Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. J Antimicrob Chemother. 67:995-1000.. 2012.
Genotypic resistance testing in routine clinical care. Curr Opin HIV AIDS. 6:251-7.. 2011.
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis.. 2016.
HIV type-1 drug resistance in antiretroviral treatment-naive adults infected with non-B subtype virus in the United Kingdom. Antivir Ther. 15:985-91.. 2010.
HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004. Pediatr Infect Dis J. 27:457-9.. 2008.
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother. 71(12). 2016.
HIV-1 subtype and virological response to antiretroviral therapy: a confirmatory analysis. Clin Infect Dis. 56:162-3.. 2013.
The HIV-1 subtype C epidemic in South America is linked to the United Kingdom. PLoS One. 5:e9311.. 2010.
HIV-1 transmission patterns in men who have sex with men: insights from genetic source attribution analysis.. AIDS Res Hum Retroviruses.. 2019.
Identification of accessory mutations associated with high-level resistance in HIV-1 reverse transcriptase. AIDS. 21:447-55.. 2007.
The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr. 49:196-204.. 2008.
The impact of HIV drug resistance testing on changes to treatment. AIDS. 25:603-10.. 2011.
The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults. AIDS. 27:2245-53.. 2013.
The impact of the 0-0 cell on measures of amino acid covariation. AIDS. 24:159-60.. 2010.
Impact of transmitted drug-resistance on treatment selection and outcome of first-line Highly Active Antiretroviral Therapy (HAART). J Acquir Immune Defic Syndr. 53:633-9.. 2010.
Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. J Antimicrob Chemother. 71:1352-60.. 2016.
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS. 28:773-80.. 2014.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med. 9:27-40.. 2008.
Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Infect Dis. 198:470-80.. 2008.